Not all subclones matter in CLL.

R. Rosenquist,L. Sutton

DOI: https://doi.org/10.1182/blood-2016-02-699041

IF: 20.3

2016-04-28

Blood

Abstract:In this issue of Blood , [Nadeu et al][1] delve deep into the genomes of patients diagnosed with chronic lymphocytic leukemia (CLL) and report on the clinical implications of tumor heterogeneity in the era of next-generation sequencing (NGS).[1][2] While clonal evolution is common in hematologic

Medicine,Biology

What problem does this paper attempt to address?

Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia

Wade L Schulz,Thomas JS Durant,Henry Rinder,Christopher A Tormey,Richard Torres,Brian R Smith,Karl M Hager,John G Howe,Alexa J Siddon

DOI: https://doi.org/10.1182/blood.v126.23.1385.1385

IF: 20.3

2015-12-03

Blood

Abstract:Abstract Background: Tumor heterogeneity has been documented in several malignancies and is generally associated with more aggressive disease and poorer prognosis. While heterogeneity has been documented in acute myeloid leukemia (AML), risk prognosis in AML is currently assessed by cytogenetics and the presence of recurrent mutations in genes such as FLT3 and NPM1, which are typically tested on a single gene basis. Prior approaches to identify molecular clonality have been laborious and therefore of limited clinical utility. The advent of next generation sequencing (NGS), however, allows for the rapid assessment of subclones within tumor populations. Currently, the prognostic significance of tumor heterogeneity in AML is not well defined. Therefore, this pilot study assessed the clinical significance of molecular clonality in AML using data generated by an NGS platform. Methods: We selected patients with de novo AML who had blood or bone marrow submitted for sequencing at initial diagnosis. Patients who subsequently elected for comfort measures only without receiving AML-directed therapy were excluded. Study patients were sequenced with a 25 gene NGS panel on the Ion Torrent platform. This panel included genes that have been shown to be frequently mutated in AML and which lead to increased cellular proliferation or impaired differentiation, with particular emphasis on therapeutic and prognostic mutations. Germline mutations, identified by allelic fraction and/or minor allele frequency, were excluded. Remaining somatic mutations were analyzed with software employing a variational Bayesian algorithm to predict tumor heterogeneity such that patients were assessed for the presence of tumor heterogeneity (≥2 predicted clones) at the time of diagnosis. Heterogeneity was recorded and compared to several clinical parameters, including post-chemotherapy survival at 120 days, patient age, gender, karyotype, and association with the recurrent genetic mutations NPM1, FLT3-ITD, and CEBPA. Results: Twenty patients met the study criteria of de novo AML and elected to receive therapy. The mean age at diagnosis was 59 years (38-77 years); overall survival was 75% at 120 days. Half of the patients (n=10) were determined to have ≥2 clones. Patients with either a complex karyotype or the FLT3-ITD mutation were classified as high risk (n=11). While survival at 120 days was lower in the high risk group (64%) compared to normal risk subjects (89%), this difference did not reach statistical significance (p=0.19). By contrast, patients with tumor heterogeneity (≥2 clones) had significantly lower 120 day survival (50%) when compared to AML patients with a single clone (100%) (p=0.01). There was no correlation between patients with multiple clones and high risk classification (p=0.18). Conclusions: These pilot data present some of the first prospective evidence that heterogeneity detected by NGS is an adverse prognostic indicator for early survival in de novo AML post-chemotherapy. This finding may not be surprising given that the presence of tumor heterogeneity has been shown to confer adverse prognostic risk in several solid malignancies. Still, this early impact of molecular clonality in AML may have important consequences on choice of therapy. Further prospective studies are needed to confirm our findings and to determine the long-term outcomes in AML patient subsets, as well as examining whether a distinct approach to therapy in AML patients with clonal heterogeneity leads to improved early survival. Figure 1. Figure 1. Figure 2. Figure 2. Disclosures No relevant conflicts of interest to declare.

hematology
Deregulation and Shattering of Chromosomal Segments Containing Multiple Oncogenic Targets in the Pathogenesis of Diffuse Large B Cell Lymphoma, Not Otherwise Specified (DLBCL, NOS)

Ashwini Yenamandra,Rebecca Smith,Adam Seegmiller,Brianna Smith,Debra Friedman,Christine Smith,Ashwini K. Yenamandra,Rebecca B. Smith,Adam C. Seegmiller,Brianna N. Smith,Debra L. Friedman,Christine M. Smith

DOI: https://doi.org/10.3390/dna4030021

2024-09-18

DNA

Abstract:Diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS) is the most common type of non-Hodgkin lymphoma (NHL). Significant efforts have been focused on utilizing advanced genomic technologies to further subclassify DLBCL, NOS into clinically relevant subtypes. These efforts have led to the implementation of novel algorithms to support optimal risk-oriented therapy and improvement in the overall survival of DLBCL patients. The pathogenesis of DLBCL at the molecular level indicates copy number variation (CNV) as one of the major forms of genetic alterations in the somatic mutational landscape. Random deregulation that results in complex breaks of chromosomes and restructuring of shattered chromosomal segments is called chromothripsis. Gene expression changes influenced by chromothripsis have been reported in cancer and congenital diseases. This chaotic phenomenon results in complex CNV, gene fusions, and amplification and loss of tumor suppressor genes. We present herein a summary of the most clinically relevant genomic aberrations, with particular focus on copy number aberrations in a case that highlights DLBCL, NOS arising from relapsed Hodgkin lymphoma. The focus of our study was to understand the relationship between the clinical, morphological, and genomic abnormalities in DLBCL, NOS through multiple techniques for therapeutic considerations.
Clinical Impact of the Quantitative Subclonal Architecture in Chronic Lymphocytic Leukemia

Ferran Nadeu,Julio Delgado,Guillem Clot,David Martín-García,Tycho Baumann,Magda Pinyol,Pedro Jares,Sílvia Beà,Itziar Salaverria,Alba Navarro,Helena Suárez-Cisneros,Marta Aymerich,Maria Rozman,Neus Villamor,Dolors Colomer,Marcos González,Miguel Alcoceba,María José Terol,Enrique Colado,Armando López-Guillermo,Xose S Puente,Carlos Lopez-Otin,Anna Enjuanes,Elias Campo

DOI: https://doi.org/10.1182/blood.v128.22.2024.2024

IF: 20.3

2016-12-02

Blood

Abstract:Abstract Introduction Recent large scale genomic studies have disclosed the heterogeneity of the mutational landscape of chronic lymphocytic leukemia (CLL). The remarkable genomic plasticity of this disease has been further emphasized by the complex subclonal composition recognized in some tumors. Initial studies using high-coverage next generation sequencing (NGS) have revealed the prognostic impact of mutations at very low allelic frequency. The results of these studies have opened a new perspective where the proportion of cells carrying specific driver mutations rather than just the presence or absence of the alterations may be relevant to understand the evolution of this disease. However, the information generated has been limited to a small subset of CLL driver genes. The aims of this study were to define the deep mutational architecture of 28 frequently altered driver genes in CLL and determine the relevance of the subclonal quantitative composition in the progression of the disease. Methods Highly purified tumor samples from 406 untreated CLL patients were included in this study. Ultra-deep NGS of the 28 target genes was performed using the Acces-Array system (Fluidigm) (ATM, TP53, SF3B1, BIRC3, XPO1, RPS15, FBXW7, DDX3X, POT1, KLHL6, MGA, MYD88, IRF4, BRAF, NXF1, BCOR, ZNF292, NRAS, KRAS, CCND2, TRAF3, ZMYM3, MED12) or the Nextera-XT DNA library preparation kit (Illumina) (NOTCH1, NFKBIE, EGR2, PIM1, DTX1) before sequencing in a MiSeq (Illumina). A robust bioinformatic pipeline followed by an extensive verification process allowed the detection of mutations down to 0.3% of variant allele frequency (VAF). Copy number alterations were investigated by high density SNP-arrays in 376 cases. We calculated the cancer cell fraction (CCF) carrying each specific mutation using the PyClone algorithm. The prognostic impact of the mutations was evaluated for time to first treatment (TTFT) and overall survival from the time of sampling. Results The mutational frequency observed for virtually all genes was higher than in similar previous studies of population based CLL at diagnosis. We detected mutations with a VAF below the Sanger sequencing threshold (VAF <12%) in 24 (86%) of the genes, corresponding to 40% of all mutations identified (median per gene of 45%, range 7-68%). Most genes showed a continuous spectrum of mutated CCFs except MYD88, KLHL6, EGR2, NOTCH1, SF3B1, and FBXW7 that displayed a bimodal distribution with most of the cases carrying either small (CCF 80%) mutated clones. Overall, among the 260/406 (64%) cases carrying at least one mutation in any of the genes analyzed, a major mutated clone (CCF >80%) was only identified in half of the patients (127, 49%). Convergent mutational evolution, defined as the acquisition of independent genetic mutations in the same gene, was observed in 19 (68%) of the 28 genes analyzed, being present in 66/260 (25%) mutated cases. The number of cases with convergent evolution was directly related to the global mutational frequency of the gene. The clinical relevance of the mutations appeared to be gene specific and related to the quantitative magnitude of the different subclones. We identified three major patterns of specific gene CCF that influenced the prognosis of the patient: 1) CCF independent pattern in which the mere detection of a mutation at any CCF conferred an adverse prognosis (TP53, ATM, POT1, NFKBIE, XPO1, or RPS15 among others); 2) CCF gradual pattern in which the poor prognostic impact was a continuous variable directly related to the size of the mutated clone (SF3B1); and 3) CCF clonal pattern in which the prognostic impact of the mutations was a categorical variable defined by a certain threshold of the mutated clone (NOTCH1, BIRC3, EGR2, FBXW7). On the other hand, cases with convergent mutational evolution had a tendency to a shorter TTFT when compared to mutated cases without this phenomenon. Conclusions In conclusion, the emergence of subclonal mutations is a general and dynamic phenomenon in CLL that seems to involve virtually all driver genes and occurs at different time points of the disease. The clinical impact of the clonal architecture of the tumor is gene specific and related to the magnitude of the respective subclone. These findings provide new insights on the relevance of the subclonal mutational profile in CLL and the importance of quantitative mutational analyses for the management of the patients. Disclosures No relevant conflicts of interest to declare.

hematology
Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia

Brooks A. Benard,Logan B. Leak,Armon Azizi,Daniel Thomas,Andrew J. Gentles,Ravindra Majeti

DOI: https://doi.org/10.1038/s41467-021-27472-5

IF: 16.6

2021-12-01

Nature Communications

Abstract:Abstract The impact of clonal heterogeneity on disease behavior or drug response in acute myeloid leukemia remains poorly understood. Using a cohort of 2,829 patients, we identify features of clonality associated with clinical features and drug sensitivities. High variant allele frequency for 7 mutations (including NRAS and TET2 ) associate with dismal prognosis; elevated GATA2 variant allele frequency correlates with better outcomes. Clinical features such as white blood cell count and blast percentage correlate with the subclonal abundance of mutations such as TP53 and IDH1 . Furthermore, patients with cohesin mutations occurring before NPM1 , or transcription factor mutations occurring before splicing factor mutations, show shorter survival. Surprisingly, a branched pattern of clonal evolution is associated with superior clinical outcomes. Finally, several mutations (including NRAS and IDH1 ) predict drug sensitivity based on their subclonal abundance. Together, these results demonstrate the importance of assessing clonal heterogeneity with implications for prognosis and actionable biomarkers for therapy.

multidisciplinary sciences
Clonal Evolution in Chronic Lymphocytic Leukemia

Sami Malek,Kamlai Saiya-Cork,Erlene Seymour,Cheng Li,Kerby Shedden,Peter Ouillette

DOI: https://doi.org/10.1182/blood.v120.21.3870.3870

IF: 20.3

2012-01-01

Blood

Abstract:Abstract Abstract 3870 Introduction: The phenotypic characterization of dominant CLL clones at various disease stages using multiple experimental approaches has deepened our understanding of CLL biology and clinical behavior. However, much less is known about the phenotype and phenotypic changes that occur in CLL over time and with disease progression when measured longitudinally. Analysis of large CLL cohorts at various disease time points is needed to better capture the dynamics of this disease. Methods: A total of 143 CLL cases were surveyed at trial enrollment and longitudinally for changes in acquired genomic copy number aberrations (aCNA), acquired uniparental disomy (aUPD), and somatically acquired mutations in the genes TP53, SF3B1, and NOTCH1. On an unselected basis, longitudinal samples were studied at a minimum of 24 months after initial sample procurement in the case of no therapeutic intervention or at the time of relapse after chemotherapy. The median time span between enrollment and longitudinal samples was 40.5 months for samples without intervening therapy (range 9–79 mos.) and 42 months for relapsed cases (range 7–74 mos.). One hundred eight cases did not receive therapeutic interventions in-between sample procurements, while 35 were relapsed from therapy. In 13 cases, time spans less than 24 months were allowed if the patient carried a high-risk CLL genomic feature or if limited follow-up samples were available. Cells were purified by flow cytometry sorting of viable CD19+ and CD3+ cells. DNA samples isolated from paired tumor and normal samples were studied for aCNA using Affymetrix SNP 6.0 arrays and the software program dChip. Samples were also analyzed for LOH/aUPD via internally-developed software. aCNA were scored through visual interpretations of the dChip display of paired samples and corroborated through an algorithmic lesion calling method. Finally, the genes TP53 exons 2–10, SF3B1 exons 13–17, and NOTCH1 exons 34 were resequenced in all samples. Results: The dominant phenomenon observed in this large CLL cohort was genomic stability for aCNA and gene mutations, which was detected in 116 (81%) of cases analyzed. Importantly however, 27 (19%) of CLL cases differed between enrollment and longitudinal follow-up. Within this subgroup of cases, 21 cases harbored changes in aCNA/LOH/aUPD, while 7 cases carried a change in the mutation status of TP53, NOTCH1 or SF3B1 (one case had both aCNA and mutation changes). Specifically, 19 cases with aCNA/LOH/aUPD changes added lesions at longitudinal analysis and lost none: clear examples of clonal evolution. Four cases added TP53 mutations and two cases added a NOTCH1 mutation. Conversely, TP53 mutations were never lost, while one case with a novel TP53 mutation lost a pre-existing NOTCH1 mutation and one case lost a SF3B1 mutation. No case gained a SF3B1 mutation. Only one CLL case at relapse demonstrated an aCNA/LOH/aUPD pattern that was completely unrelated to the dominant CLL clone at enrollment. Conclusion: In this report, we describe genomic changes in a cohort of 143 CLL cases analyzed longitudinally. This study constitutes the largest analysis of such changes reported to date. Our overall estimates of genomic instability in CLL are likely underestimates of the true frequency, given the observed natural selection against aggressive CLL inherent in this type of analysis. From this data several conclusions can be reached that have implications for our understanding of CLL clonal dynamics and the effects of therapy on clonal evolution/emergence: i) the vast majority of genomic changes are acquisitions of new lesions/mutations combined with the retention of pre-existing lesions–therefore persistence of antecedent clones underlies CLL relapse and disease persistence; ii) CLL cases demonstrating clonal evolution were enriched for cases that received intervening chemotherapy (∼50% in this cohort); iii) the acquisition of TP53 mutations followed intervening chemotherapy, providing further impetus to carefully select patients for chemotherapy; iv) NOTCH1 mutations were rarely acquired over time and in one case lost; v) no SF3B1 mutations were acquired over time and in one case lost; vi) the latter two observations argue against a strong driver role for these mutations in CLL progression/relapse; vii) the acquisition of aCNA/LOH/aUPD and gene mutation was non-overlapping, indicative of distinct roles for each aberration type in CLL evolution. Disclosures: No relevant conflicts of interest to declare.
Tumor heterogeneity of acute myeloid leukemia: insights from single-cell sequencing

AiLi Chen,ShaoYan Hu,Qian-Fei Wang

DOI: https://doi.org/10.1097/bs9.0000000000000015

2019-08-01

Blood Science

Abstract:Individual tumors comprise genetically and epigenetically heterogeneous subclones, each of which is presumably associated with a distinct function, such as self-renewal or drug sensitivity. The dissection of such intratumoral heterogeneity is crucial to understand how tumors evolve during disease progression and under the selection of therapeutic intervention. As a paradigm of cancer intratumoral heterogeneity and clonal evolution, acute myeloid leukemia (AML) has been shown to possess complex clonal architecture based on karyotype studies, as well as deep sequencing of mixed cellular populations using next-generation sequencing (NGS) technologies. The recent development of single-cell sequencing (SCS) methods provides a powerful tool to allow analysis of genomes, transcriptomes, proteomes, and epigenomes at an individual cell level. The technologies applied in AML have broadened our understanding of AML heterogeneity and provided new insights for the development of novel therapeutic strategies. In this review, we summarize the progress in the research of AML heterogeneity using SCS technology and discuss the limitations and future direction regarding how SCS can contribute to AML prognosis and treatment.

English Else
Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia

Xiao Chen,Han Zhu,Chun Qiao,Sishu Zhao,Lu Liu,Yan Wang,Huimin Jin,Sixuan Qian,Yujie Wu

DOI: https://doi.org/10.1080/16078454.2020.1858610

IF: 2.264

Hematology

Abstract:Objectives: The study aims to understand geneome diversiﬁcation and complexity that developed in Acute myeloid leukemia (AML). Methods: Next-generation sequencing (NGS) was used to identify the genetic proﬁles of 22 genes relevant to hematological malignancy in 204 patients with de novo non-M3 AML. Results: At time of initial diagnosis, at least one mutation was identified in 80.9% of patients (165/204). The most commonly mutated gene was NPM1 (22.1%), followed by ASXL1 (18.1%), TET2 (18.1%), IDH2 (15.7%), CEBPA (14.7%), FLT3-ITD (13.2%) and DNMT3A (11.8%). Mutations landscape analysis indicated several patterns of co-occurring and mutual exclusive gene mutations. Some correlation was observed between gene mutations and clinicohematological features. Multivariate analysis showed that age >60 years, karyotypes, IDH2 and KIT mutations were the independent unfavorable prognostic factors for OS; NPM1-mut/ FLT3-ITD-wt was independently correlated with prolonged OS; whereas the independent poor risk factors for RFS were karyotypes, high WBC and RUNX1 mutation. According to different genotype demonstrated by multivariate analysis, 163 patients with intermediate-risk cytogenetics were classified into three subgroups: patients with NPM1-mut/ FLT3-ITD-wt or biallelic CEBPA mutation as favorable risk, patients with KIT, IDH2, TP53 or NRAS mutations as unfavorable risk, and the remaining was the intermediate risk. We also obtain information of clonal evolution during leukemia progression by observing five patients who underwent repeat NGS at relapse in our cohort. Conclusion: NGS techniques is a useful tool for discovering related gene mutations and clonal evolution in AML genomes, leading to novel targeted therapeutic approaches that could improve patients outcomes.
Tumor subclones, where are you?

Xianbin Su,Futong Tian,Yi Shi,Linan Zhao,Guoliang Yang,Kun-Yan He,Q. Long,Gangcai Xie,Ze-Guang Han,Lan Wang,Xiaolin Li,Shihao Bai

DOI: https://doi.org/10.1101/2022.07.10.499466

2022-07-11

bioRxiv

Abstract:Introduction Tumor clonal structure is closely related to future progression, which has been mainly investigated via mutation abundance clustering in bulk sample. With limited studies at single-cell resolution, a systematic comparison of the two approaches is still lacking. Methods Here, using bulk and single-cell mutational data from liver and colorectal cancers, we would like to check the possibility of obtaining accurate tumor clonal structures from bulk-level analysis. We checked whether co-mutations determined by single-cell analysis had corresponding bulk variant allele frequency (VAF) peaks. We examined VAF ranges for different groups of co-mutations, and also the possibility of discriminating them. Results While bulk analysis suggested absence of subclonal peaks and possibly neutral evolution in some cases, single-cell analysis identified co-existing subclones. The overlaps of bulk VAF ranges for co-mutations from different subclones made it difficult to separate them, even with other parameter introduced. The difference between mutation cluster and tumor subclone is accountable for the challenge in bulk clonal deconvolution, especially in case of branched evolution as shown in colorectal cancer. Conclusion Complex subclonal structures and dynamic evolution are hidden under the seemingly clonal neutral pattern at bulk level, suggesting single-cell analysis will be needed to avoid under-estimation of tumor heterogeneity. Research Highlights Bulk-level mutation abundance clusters are not equal to tumor subclones. Different groups of co-mutations could not be discriminated at bulk-level. Single-cell mutational analysis can identify rather than infer tumor subclones. Co-existing tumor subclones may have clonal neutral appearance at bulk-level. Lay summary Systematic comparison of tumor clonal structure differences between bulk and single-cell mutational analysis is lacking. Here we performed such as study and found that complex subclonal structures and dynamic evolution are hidden under clonal neutral appearance at bulk level in liver and colorectal cancers, suggesting single-cell analysis will be needed to avoid under-estimation of tumor heterogeneity.

Biology,Medicine
Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia

Gage S. Black,Xiaomeng Huang,Yi Qiao,Philip Moos,Deepa Sampath,Deborah M. Stephens,Jennifer A. Woyach,Gabor T. Marth

DOI: https://doi.org/10.1101/2024.03.15.585298

2024-03-18

Abstract:Bruton’s tyrosine kinase (BTK) inhibitors are effective for the treatment of chronic lymphocytic leukemia (CLL) due to BTK’s role in B cell survival and proliferation. Treatment resistance is most commonly caused by the emergence of the hallmark mutation that inhibits drug binding. In this study, we aimed to investigate whether the presence of additional CLL driver mutations in cancer subclones harboring a mutation accelerates subclone expansion. In addition, we sought to determine whether mutated subclones exhibit distinct transcriptomic behavior when compared to other cancer subclones. To achieve these goals, we employ our recently published method ( ) that combines bulk DNA sequencing and single-cell RNA sequencing (scRNA-seq) data to genotype individual cells for the presence or absence of subclone-defining mutations. While the most common approach for scRNA-seq includes short-read sequencing, transcript coverage is limited due to the vast majority of the reads being concentrated at the priming end of the transcript. Here, we utilized MAS-seq, a long-read scRNAseq technology, to substantially increase transcript coverage across the entire length of the transcripts and expand the set of informative mutations to link cells to cancer subclones in six CLL patients who acquired mutations during BTK inhibitor treatment. We found that -mutated subclones often acquire additional mutations in CLL driver genes, leading to faster subclone proliferation. When examining subclone-specific gene expression, we found that in one patient, -mutated subclones are transcriptionally distinct from the rest of the malignant B cell population with an overexpression of CLL-relevant genes.

Genomics
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

Florian Scherer,David M Kurtz,Aaron M Newman,Henning Stehr,Alexander F M Craig,Mohammad Shahrokh Esfahani,Alexander F Lovejoy,Jacob J Chabon,Daniel M Klass,Chih Long Liu,Li Zhou,Cynthia Glover,Brendan C Visser,George A Poultsides,Ranjana H Advani,Lauren S Maeda,Neel K Gupta,Ronald Levy,Robert S Ohgami,Christian A Kunder,Maximilian Diehn,Ash A Alizadeh

DOI: https://doi.org/10.1126/scitranslmed.aai8545

2016-11-09

Abstract:Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor behavior and outcomes, yet the identification of poor-risk groups remains challenging. In addition, the biology underlying these differences is incompletely understood. We hypothesized that characterization of mutational heterogeneity and genomic evolution using circulating tumor DNA (ctDNA) profiling could reveal molecular determinants of adverse outcomes. To address this hypothesis, we applied cancer personalized profiling by deep sequencing (CAPP-Seq) analysis to tumor biopsies and cell-free DNA samples from 92 lymphoma patients and 24 healthy subjects. At diagnosis, the amount of ctDNA was found to strongly correlate with clinical indices and was independently predictive of patient outcomes. We demonstrate that ctDNA genotyping can classify transcriptionally defined tumor subtypes, including DLBCL cell of origin, directly from plasma. By simultaneously tracking multiple somatic mutations in ctDNA, our approach outperformed immunoglobulin sequencing and radiographic imaging for the detection of minimal residual disease and facilitated noninvasive identification of emergent resistance mutations to targeted therapies. In addition, we identified distinct patterns of clonal evolution distinguishing indolent follicular lymphomas from those that transformed into DLBCL, allowing for potential noninvasive prediction of histological transformation. Collectively, our results demonstrate that ctDNA analysis reveals biological factors that underlie lymphoma clinical outcomes and could facilitate individualized therapy.
Molecular map of chronic lymphocytic leukemia and its impact on outcome

Binyamin A. Knisbacher,Ziao Lin,Cynthia K. Hahn,Ferran Nadeu,Martí Duran-Ferrer,Kristen E. Stevenson,Eugen Tausch,Julio Delgado,Alex Barbera-Mourelle,Amaro Taylor-Weiner,Pablo Bousquets-Muñoz,Ander Diaz-Navarro,Andrew Dunford,Shankara Anand,Helene Kretzmer,Jesus Gutierrez-Abril,Sara López-Tamargo,Stacey M. Fernandes,Clare Sun,Mariela Sivina,Laura Z. Rassenti,Christof Schneider,Shuqiang Li,Laxmi Parida,Alexander Meissner,François Aguet,Jan A. Burger,Adrian Wiestner,Thomas J. Kipps,Jennifer R. Brown,Michael Hallek,Chip Stewart,Donna S. Neuberg,José I. Martín-Subero,Xose S. Puente,Stephan Stilgenbauer,Catherine J. Wu,Elias Campo,Gad Getz

DOI: https://doi.org/10.1038/s41588-022-01140-w

IF: 30.8

2022-08-05

Nature Genetics

Abstract:Recent advances in cancer characterization have consistently revealed marked heterogeneity, impeding the completion of integrated molecular and clinical maps for each malignancy. Here, we focus on chronic lymphocytic leukemia (CLL), a B cell neoplasm with variable natural history that is conventionally categorized into two subtypes distinguished by extent of somatic mutations in the heavy-chain variable region of immunoglobulin genes (IGHV). To build the 'CLL map,' we integrated genomic, transcriptomic and epigenomic data from 1,148 patients. We identified 202 candidate genetic drivers of CLL (109 new) and refined the characterization of IGHV subtypes, which revealed distinct genomic landscapes and leukemogenic trajectories. Discovery of new gene expression subtypes further subcategorized this neoplasm and proved to be independent prognostic factors. Clinical outcomes were associated with a combination of genetic, epigenetic and gene expression features, further advancing our prognostic paradigm. Overall, this work reveals fresh insights into CLL oncogenesis and prognostication.

genetics & heredity
Abstract 1516: Deep profiling of T-cell repertoire and tumor heterogeneity in chronic lymphocytic leukemia patients following allogeneic T-cell therapy

Celine Kerros,John P. Miller,Xizeng Mao,Haven R. Garber,Hannah C. Beird,Jianhua Zhang,Jason Roszik,Paul Leonard,Li Zhao,Sahil Seth,Pei Lin,Huandong Sun,William G. Wierda,Issa F. Khouri,Karen Clise-Dwyer,Andrew Futreal,Shoudan Liang,Koppikar Priya,Jeffrey Molldrem

DOI: https://doi.org/10.1158/1538-7445.am2020-1516

2020-08-13

Tumor Biology

Abstract:Abstract Chemotherapy/ targeted therapy are both known to trigger evolution of treatment resistant clones that can lead to relapse. Allogeneic stem cell transplant (alloSCT) for refractory Chronic Lymphocytic Leukemia (CLL) patients is associated with better outcomes. We hypothesized that allogeneic T-cell immunotherapies, including alloSCT and donor lymphocyte infusion (DLI) would impact tumor evolution through the application of selective immunologic pressure with reciprocal changes in the T-cell compartment. Here, we tested a cohort of 24 heavily pre-treated CLL patients treated. Treatments consisted of alloSCT alone, or with follow-up DLI, which are two established mediators of effective Graft versus Leukemia (GVL). Our cohort included 11 patients who relapsed (denoted as non-responder, NR) after alloSCT and 13 patients who had complete response (CR) after alloSCT, with 11/13 patients showing durable CR with a median post-transplant overall survival (OS) of 9.8 years. We mapped the evolutionary trajectories of tumor cells by whole exome sequencing (WES) of sort purified CLL in post-transplant relapsed patients. To investigate changes in immune repertoire and gene expression post-transplant, CD3 positive T-cells from peripheral blood and bone marrows of CLL patients at complete donor chimerism were analyzed both at bulk and at the single cell level. We found evidence of subclonal leukemic evolution in the majority of our CLL patient cohort after nonmyeloablative HLA-matched alloSCT. Different patterns of CLL evolution were observed, and these changes included putative CLL drivers in every case. In all of the 11 patients with longitudinal post-alloSCT samples available, we observed branched CLL evolution in 4 patients, linear evolution in 4 patients, and no evolution in 3 patients. These data suggest that differential sensitivity of leukemic subclones to allogeneic T cell killing may underlie the branched and linear evolution that we observed, and therefore can shape leukemic subclonal architecture after transplant. Of note, we found that clonal CLL was more responsive to alloSCT in comparison to CLL with subclonal disease architecture.To identify T-cells with GVL potential, we first cataloged potential neoantigens by screening mutated regions in CLL with in silico HLA binding prediction models. Neoantigen specific T-cells were then sorted from longitudinal peripheral blood samples using tetramers, followed by identification of GVL specific TCR in both bulk and single cell setting. We were able to identify T-cells that coevolved with specific tumorigenic lesions in a subset of CLL patients. Taken together, our results suggest that donor-derived antigen-specific T-cells mediate clonal selection of CLL with concurrent changes in allogeneic T-cells, and that these changes can be monitored in longitudinal patient samples. Citation Format: Celine Kerros, John P. Miller, Xizeng Mao, Haven R. Garber, Hannah C. Beird, Jianhua Zhang, Jason Roszik, Paul Leonard, Li Zhao, Sahil Seth, Pei Lin, Huandong Sun, William G. Wierda, Issa F. Khouri, Karen Clise-Dwyer, Andrew Futreal, Shoudan Liang, Koppikar Priya, Jeffrey Molldrem. Deep profiling of T-cell repertoire and tumor heterogeneity in chronic lymphocytic leukemia patients following allogeneic T-cell therapy [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1516.

English Else
Big Bang Tumor Growth and Clonal Evolution

Ruping Sun,Zheng Hu,Christina Curtis

DOI: https://doi.org/10.1101/cshperspect.a028381

2017-01-01

Cold Spring Harbor Perspectives in Medicine

Abstract:The advent and application of next-generation sequencing (NGS) technologies to tumor genomes has reinvigorated efforts to understand clonal evolution. Although tumor progression has traditionally been viewed as a gradual stepwise process, recent studies suggest that evolutionary rates in tumors can be variable with periods of punctuated mutational bursts and relative stasis. For example, Big Bang dynamics have been reported, wherein after transformation, growth occurs in the absence of stringent selection, consistent with effectively neutral evolution. Although first noted in colorectal tumors, effective neutrality may be relatively common. Additionally, punctuated evolution resulting from mutational bursts and cataclysmic genomic alterations have been described. In this review, we contrast these findings with the conventional gradualist view of clonal evolution and describe potential clinical and therapeutic implications of different evolutionary modes and tempos.
Intratumoral Genetic Heterogeneity and Number of Cytogenetic Aberrations Provide Additional Prognostic Significance in Chronic Lymphocytic Leukemia

Shuhua Yi,Zengjun Li,Dehui Zou,Gang An,Rui Cui,Shizhen Zhong,Heng Li,Wenjie Xiong,Chenwen Li,Weiwei Chen,Wei Liu,Rui Lv,Zhen Yu,Huijun Wang,Yan Xu,Keshu Zhou,Kun Ru,Jianxiang Wang,Tao Cheng,Lugui Qiu

DOI: https://doi.org/10.1038/gim.2016.81

IF: 8.864

2017-01-01

Genetics in Medicine

Abstract:Purpose: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with cytogenetic aberrations that are still considered the gold standard of prognostic factors. However, heterogeneity remains within each cytogenetic group, especially in patients with concomitant cytogenetic aberrations. Methods: A panel of DNA probes was used to detect cytogenetic aberrations, including RB1/D13S25 at 13q14, ATM at 11q22, TP53 at 17p13, CEP12 and IGH translocation at 14q32, by fluorescence in situ hybridization. A comprehensive method integrating the number of cytogenetic aberrations and intratumoral genetic heterogeneity was used to analyze the prognosis for patients with concomitant aberrations. Results: Within the conventional favorable or neutral prognostic groups (i.e., with del 13q, trisomy 12, and/or t(14q32)), the coincidence of these three aberrations worsened survival in terms of time to first therapy, progression-free survival, and overall survival. However, within the conventional unfavorable prognostic group (i.e., del 11q or del 17p), patients with a minor unfavorable clone had an unexpected survival advantage compared with patients with a major unfavorable clone. A new cytogenetic prognostic system that integrates the number of cytogenetic aberrations and intratumoral genetic subclones was more precise than the conventional system. Conclusion: The number of cytogenetic aberrations and the size of intratumoral genetic subclones should be comprehensively considered to determine the prognosis for CLL. Genet Med 19 2, 182–191.
Whole Genome Sequencing Defines the Clonal Architecture and Genomic Evolution in Myeloma: Tumor Heterogeneity with Continued Acquisition of New Mutational Change

Nikhil C. Munshi,Herve Avet-Loiseau,Philip J. Stephens,Graham R. Bignell,Yu-Tzu Tai,Masood Shammas,Cheng Li,Parantu K. Shah,Mariateresa Fulciniti,Jagannath Pal,Ankit V. Vahia,Paul G. Richardson,Stephane Minvielle,Peter Campbell,Kenneth C. Anderson,Andrew Futreal

DOI: https://doi.org/10.1182/blood.v118.21.297.297

IF: 20.3

2011-01-01

Blood

Abstract:Abstract 297This icon denotes a clinically relevant abstract
Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications

Paul J Hengeveld,Mark-David Levin,P Martijn Kolijn,Anton W Langerak

DOI: https://doi.org/10.1016/j.exphem.2020.09.194

Abstract:B-Cell receptor (BCR) sequencing has been the force driving many recent advances in chronic lymphocytic leukemia (CLL) research. Here, we discuss the general principles, revelations, and applications of reading the BCR immunome in the context of CLL. First, IGHV mutational status, obtained by measuring the mutational imprint on the IGHV gene of the CLL clonotype, is the cornerstone of CLL risk stratification. Furthermore, the discovery of "BCR-stereotyped" groups of unrelated patients that share not only a highly similar BCR on their leukemic clone, but also certain clinical characteristics has provided insights key to understanding disease ontogeny. Additionally, whereas the BCR repertoire of most CLL patients is characterized by a single dominant rearrangement, next-generation sequencing (NGS) has revealed a rich subclonal landscape in a larger than previously expected proportion of CLL patients. We review the mechanisms underlying these "multiple dominant" cases, including V(D)J-recombination errors, failure of allelic exclusion, intraclonal diversification, and "true" bi- or oligoclonality, and their implications, in detail. Finally, BCR repertoire sequencing can be used for sensitive quantification of minimal residual disease to potentially unprecedented depth. To surmount pitfalls inherent to this approach and develop internationally harmonized protocols, the EuroClonality-NGS Working Group has been established.
Genomics of diffuse large B cell lymphoma

Youngil Koh

DOI: https://doi.org/10.5045/br.2021.2021049

2021-04-30

Blood Research

Abstract:Next generation sequencing (NGS) technology has revealed the heterogeneity of diffuse large B-cell lymphoma (DLBCL) from a mutation perspective. Accordingly, the conventional cell of origin-based classification of DLBCL has changed to a mutation-based classification. Mutation analysis delineates that B-cell receptor pathway activation, EZH2 mutation, and NOTCH mutations are distinctive drivers of DLBCL. Moreover, the combination of RNA expression data and DNA mutation results suggests similarity between DLBCL subtypes and other non-Hodgkin lymphomas. NGS-based dissection of DLBCL would be the cornerstone for precision treatment in this heterogeneous disease in the near future.
Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution—a proof of principle study

Dominik Nann,Achim Rau,Lejla Mahmutovic,Julia Steinhilber,Vanessa Meca,Birgit Federmann,Wichard Vogel,Irina Bonzheim,Leticia Quintanilla-Martinez,Falko Fend

DOI: https://doi.org/10.1007/s00428-023-03627-1

2023-08-24

Virchows Archiv

Abstract:Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and demonstration of clonal evolution on sequential BMB. Seventy-seven EDTA-decalcified BMB of 33 patients with peripheral cytopenia and/or monocytosis, including at least one follow-up biopsy/patient, were included. Initial morphological diagnoses were idiopathic cytopenia of undetermined significance (ICUS, 8 cases), MDS (without blast increase, 7 cases), MDS with increased blasts/excess blasts (MDS-IB/EB) (11 cases), and CMML (7 cases). Thirty-one genes relevant for myeloid disorders were examined using two custom AmpliSeq NGS panels. Mutations were found in the initial BMB of 5/8 cases of ICUS, thus changing the diagnosis to clonal cytopenia of unknown significance (CCUS), 5/7 MDS, 10/11 MDS-IB/EB, and 7/7 CMML. Clonal evolution was observed in 14/33 (42%) cases, mostly associated with disease progression. None of the wild-type patients acquired mutations during follow-up. NGS-based mutation profiling is a robust diagnostic tool for BMB and provides valuable additional information, especially for cases with no/minimal dysplasia, and for better risk stratification of MDS. Tracking variant allele frequency and appearance of mutations over time allows for observing clonal evolution or relapse.

pathology
Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity

Li-Hua Zhong,Zhi-Da Wu,Jian-Chao Wang,Zai-Zeng Wu,Fang-Fang Chen,Wei-Feng Zhu,Yan-Ping Chen,Gang Chen

DOI: https://doi.org/10.21037/atm-20-7574

IF: 3.616

2021-01-01

Annals of Translational Medicine

Abstract:BACKGROUND: Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin lymphoma. A comprehensive understanding of the genetic and clinical heterogeneity of ALCL may help to improve the clinical management of patients with ALCL. However, due to the rarity of the disease, the genetic heterogeneity of ALCL has not been well elucidated. This study aimed to comprehensively elucidate the mutational landscape of tumor tissue samples from patients with systemic ALCL.METHODS: Thirty-six patients with systemic ALCL were enrolled in this retrospective study. Immunohistochemistry (IHC) was performed on tumor tissues at baseline to identify anaplastic lymphoma kinase (ALK) fusions. Capture-based targeted next-generation sequencing (NGS) with a panel spanning 112 lymphoma-related genes, including ALK rearrangements, was also performed on tumor tissue samples.RESULTS: A total of 102 mutations were identified in the entire cohort. Among the 36 patients included in this analysis, 14 (38.8%) were ALK positive, as determined by IHC, while NGS showed 12 patients (33.3%) to harbor ALK rearrangements. Younger patients were more likely to have ALK-positive ALCL (P=0.011). Patients with wild-type (WT) ALK were more likely to have single-nucleotide variants (SNVs) and insertions or deletions (INDELs) than patients with ALK rearrangements (P=0.027). Among the 22 patients with WT ALK, the most commonly mutated genes were TP53 (n=6, 27.3%), followed by NOTCH1 (n=5, 22.7%), KMT2D (n=3, 13.6%), KRAS (n=3, 13.6%), TET2 (n=3, 13.6%), and JAK1 (n=2, 9.1%). Mutations in PRDM1, a commonly mutated gene in ALK-negative patients, were not detected in our ALK-negative cohort. Start-loss of beta-2-microglobulin (B2M) was detected in another patient; this patient had a favorable prognosis, with an overall survival exceeding 19 months.CONCLUSIONS: Our study revealed the unique genomic profiles of Chinese ALCL patients and represents an incremental step in deepening the understanding of the genetic heterogeneity of ALCL patients.

oncology,medicine, research & experimental
Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone

Svenja Denker,Axel Künstner,Julian Schwarting,Hanno M. Witte,Veronica Bernard,Stephanie Stölting,Philipp Lohneis,Kathrin Kusch,Nikolas von Bubnoff,Hartmut Merz,Hauke Busch,Alfred C. Feller,Niklas Gebauer

DOI: https://doi.org/10.1038/s41375-024-02305-8

2024-06-19

Leukemia

Abstract:Leukemia, Published online: 18 June 2024; doi:10.1038/s41375-024-02305-8 Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone

oncology,hematology

Not all subclones matter in CLL.

Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia

Deregulation and Shattering of Chromosomal Segments Containing Multiple Oncogenic Targets in the Pathogenesis of Diffuse Large B Cell Lymphoma, Not Otherwise Specified (DLBCL, NOS)

Clinical Impact of the Quantitative Subclonal Architecture in Chronic Lymphocytic Leukemia

Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia

Clonal Evolution in Chronic Lymphocytic Leukemia

Tumor heterogeneity of acute myeloid leukemia: insights from single-cell sequencing

Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia

Tumor subclones, where are you?

Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

Molecular map of chronic lymphocytic leukemia and its impact on outcome

Abstract 1516: Deep profiling of T-cell repertoire and tumor heterogeneity in chronic lymphocytic leukemia patients following allogeneic T-cell therapy

Big Bang Tumor Growth and Clonal Evolution

Intratumoral Genetic Heterogeneity and Number of Cytogenetic Aberrations Provide Additional Prognostic Significance in Chronic Lymphocytic Leukemia

Whole Genome Sequencing Defines the Clonal Architecture and Genomic Evolution in Myeloma: Tumor Heterogeneity with Continued Acquisition of New Mutational Change

Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications

Genomics of diffuse large B cell lymphoma

Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution—a proof of principle study

Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity

Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone